title: [Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].
authors.forename: María Dolores
authors.initials: MD
authors.lastname: García de Lucas
authors.forename: Julián
authors.initials: J
authors.lastname: Olalla
authors.forename: Marco
authors.initials: M
authors.lastname: Sempere
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1